Current and Emerging Therapies in NSCLC

Current and Emerging Therapies in NSCLC

Episodes

Specialty:

All

Year:

All

EP. 1: Case Study: Treating an Elderly Patient With Squamous NSCLC

August 21st 2013

EP. 2: Case Study: Maintenance Therapy in Squamous NSCLC

August 21st 2013

EP. 3: Case Study: Mutation-Negative Patient With Adenocarcinoma

August 21st 2013

EP. 4: PRONOUNCE Trial: Two Drug Versus Three Drug Regimens

August 21st 2013

EP. 5: Case Study: Second-Line Treatment of Adenocarcinoma

August 21st 2013

EP. 6: Case Study: MET and ALK Targeted Therapies in NSCLC

August 21st 2013

EP. 7: Case Study: Progression on ALK Inhibitors in NSCLC

August 21st 2013

EP. 8: Case Study: Treating KRAS-Mutant Adenocarcinoma

August 21st 2013

EP. 9: Targeting the Immune System in Non-Small Cell Lung Cancer

August 21st 2013

EP. 10: Novel Immunotherapy Combinations in NSCLC

August 21st 2013

EP. 11: GALAXY-1 Trial: Investigation of Hsp90 Inhibition in NSCLC

August 21st 2013

EP. 12: Selecting a First-Line EGFR Inhibitor in NSCLC

August 21st 2013

EP. 13: Conclusion: Final Thoughts on Treatment Advances in NSCLC

August 21st 2013

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments